http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014309130-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e219f4f8ae20bf7df4bd764019ae6dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c330c0eab6328b615d13312fb10e83d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2014-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_560c6ebf9645682ddb723b2e8b61c9bd |
| publicationDate | 2014-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2014309130-A1 |
| titleOfInvention | Use of MicroRNAs for Screening and Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia |
| abstract | Disclosed are microRNA biomarkers and use thereof for screening and diagnosis of prostate cancer and benign prostatic hyperplasia. This invention provides a method for screening for prostate cancer in a subject involving the steps of: (a) assaying the miRNA expression level in a test sample from the subject to be screened for prostate cancer; (b) comparing the assayed miRNA expression level of the subject to the miRNA expression level in a normal sample providing a control relative to the test sample of the subject; and (c) computing the differential expression of the miRNA from the subject, wherein the over-expression of miR-1825 or under the expression of miR-484 is indicative of prostate cancer. In another aspect, provided is a method for screening for benign prostatic hyperplasia in a subject involving the steps of: (a) assaying the miRNA expression level in a test sample from the subject to be screened for benign prostatic hyperplasia; (b) comparing the assayed miRNA expression level of the subject to the miRNA expression level in a normal sample providing a control relative to the test sample of the subject; and (c) computing the differential expression of the miRNA from the subject, wherein the under expression of miR-498 is indicative of benign prostatic hyperplasia. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10287625-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016127998-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10358681-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10480033-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11753682-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018504915-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016115312-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114672551-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10400288-B2 |
| priorityDate | 2013-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.